Clinical trials for Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)
38 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT07548710Study of SA+X in the Treatment of Newly Diagnosed AMLRuijin Hospital
- RECRUITINGN/ANCT07183878Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)First Affiliated Hospital of Zhejiang University · PI: Yanmin Zhao, MD
- RECRUITINGPHASE1, PHASE2NCT04010877Multiple CAR-T Cell Therapy Targeting AMLShenzhen Geno-Immune Medical Institute · PI: Lung-Ji Chang, Ph.D
- RECRUITINGPHASE1, PHASE2NCT06129734Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell TransplantBenjamin Tomlinson · PI: Benjamin Tomlinson, MD
- RECRUITINGEarly Phase 1NCT07126782The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCTInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT03222674Multi-CAR T Cell Therapy for Acute Myeloid LeukemiaShenzhen Geno-Immune Medical Institute · PI: Lung-Ji Chang
- RECRUITINGNCT06513273Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)Gruppo Italiano Malattie EMatologiche dell'Adulto · PI: Anna Candoni
- RECRUITINGPhase 2NCT07023588Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual DiseaseYehui Tan
- RECRUITINGPhase 1NCT07011004A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous LeukemiaMemorial Sloan Kettering Cancer Center · PI: Brian Shaffer, MD
- RECRUITINGPhase 1NCT06880354A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06580106Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AMLWake Forest University Health Sciences · PI: Brittany Ragon, MD
- ACTIVE NOT RECRUITINGPhase 1NCT06768476CART123 + Ruxolitinib in Relapsed/Refractory AMLUniversity of Pennsylvania · PI: Saar Gill, MD, PhD
- RECRUITINGPhase 2NCT06456463A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive ChemotherapyStemline Therapeutics, Inc.
- RECRUITINGN/ANCT06879847A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AMLThe First Affiliated Hospital of Soochow University · PI: Depei Wu, Prof.
- RECRUITINGPhase 1NCT06549790Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid LeukemiaNerviano Medical Sciences
- RECRUITINGPhase 2NCT06138990Pharmacoscopy-guided Clinical Standard-of-care in r/r AMLETH Zurich · PI: Alexandre Theocharides, MD PhD
- RECRUITINGEarly Phase 1NCT06541444Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid LeukemiaBase Therapeutics (Shanghai) Co., Ltd. · PI: zhiguo Long
- RECRUITINGPhase 1NCT05945849CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AMLUniversity of Pennsylvania · PI: Noelle Frey, MD
- RECRUITINGPhase 1NCT06001788Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaKura Oncology, Inc.
- RECRUITINGPhase 1NCT05949125Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic MalignanciesAvenCell Europe GmbH · PI: Tapan Maniar, MD
- RECRUITINGN/ANCT06256627The Maintenance Treatment of "ITIVA" in AML PatientsHenan Cancer Hospital · PI: Xudong None Wei, Doctor/Professor
- RECRUITINGNCT06764459Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic TreatmentsIRCCS Azienda Ospedaliero-Universitaria di Bologna · PI: Emanuela Ottaviani, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05520567A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid LeukemiaAstellas Pharma Global Development, Inc. · PI: Medical Director
- RECRUITINGPhase 2NCT05521204Olverembatinib for FGFR1-rearranged NeoplasmsThe First Affiliated Hospital of Soochow University · PI: Suning Chen
- ACTIVE NOT RECRUITINGPhase 2NCT05285813A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent FailureM.D. Anderson Cancer Center · PI: Nicholas Short, MD
- RECRUITINGPHASE1, PHASE2NCT04707300Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)Assistance Publique - Hôpitaux de Paris · PI: Olivier HERMINE, PhD & MD
- ACTIVE NOT RECRUITINGPhase 1NCT05104775A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic MalignancySichuan Baili Pharmaceutical Co., Ltd. · PI: Weili Zhao
- RECRUITINGPhase 2NCT05025098Precision Therapy Versus Standard Therapy in AML and MDS in ElderlyUniversity Hospital, Akershus · PI: Anders Erik Astrup Dahm, MD, PHD
- RECRUITINGPHASE1, PHASE2NCT04774393Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer Center · PI: Courtney DiNardo, MD
- RECRUITINGPhase 1NCT04659616Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid LeukemiaOHSU Knight Cancer Institute · PI: Elie Traer, MD PhD
- RECRUITINGPhase 1NCT04678401IS-free Treg HaploHCTDana-Farber Cancer Institute · PI: John Koreth, MBBS, DPhil
- ACTIVE NOT RECRUITINGNCT04380441Quality of Life Model for Older Patients With AMLH. Lee Moffitt Cancer Center and Research Institute · PI: Sara Tinsley, PhD, APRN
- ACTIVE NOT RECRUITINGNCT03987958A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)AbbVie · PI: ABBVIE INC.
- ACTIVE NOT RECRUITINGPhase 1NCT03766126Lentivirally Redirected CD123 Autologous T Cells in AMLUniversity of Pennsylvania
- ACTIVE NOT RECRUITINGPhase 2NCT03747757Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related FatigueM.D. Anderson Cancer Center · PI: Sriram Yennu
- ACTIVE NOT RECRUITINGPhase 2NCT02835222Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia PatientsWake Forest University Health Sciences · PI: Timothy Pardee
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03247088Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell TransplantM.D. Anderson Cancer Center · PI: Uday R Popat
- ACTIVE NOT RECRUITINGPhase 2NCT01305499A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)Hetty Carraway · PI: Hetty Carraway, MD